According to the company, Amnio-Maxx has shown significant benefits including as a safe, natural covering that improves normal wound healing outcomes, reduced inflammation, reduced fibrosis and scarring at the surgical site, decreased pain, and more.
Amnio-Maxx will be available in two forms, liquid amnion and dehydrated dual layer patches.
Royal Biologics is a life science company specializing in the advancement of regenerative medicine using proprietary technologies targeting point of care and autologous stem cell therapies.
BenevolentAI reports positive Phase Ia safety and pharmacokinetic data for BEN-8744
Thermo Fisher Scientific unveils CorEvitas registry for generalized pustular psoriasis
Nektar Therapeutics commences Phase 2b rezpegaldesleukin clinical trial for alopecia areata
Innovent Biologics doses first participant in first-in-human phase one clinical trial of IBI3002
Ananda Developments secures CBD Drug Supply Agreement for endometriosis clinical trial
Trellus Health secures agreement with major US health plan for IBD management
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP